View Single Post
  #1  
Old Thu Mar 29, 2018, 01:23 PM
Marrowforums Marrowforums is offline
Marrowforums.org
 
Join Date: Jul 2006
Posts: 919
ACH-4471 in trials for PNH treatment

Achillion Pharmaceuticals is sponsoring a tiny Phase II trial of ACH-4471, a new drug for the treatment of PNH.

ACH-4471 inhibits a specific molecule that is part of the complement process, and may reduce hemolysis.

ACH-4471 was recently approved in Europe for treatment of C3 glomerulopathy.
Reply With Quote